This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares

1 week ago 14

Jonathan Ponciano, The Motley Fool

Sun, March 15, 2026 astatine 5:27 PM CDT 4 min read

On February 17, 2026, OrbiMed Advisors reported selling 143,304 shares of Sionna Therapeutics (NASDAQ:SION), an estimated $5.43 cardinal commercialized based connected quarterly mean pricing.

According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, OrbiMed Advisors reduced its Sionna Therapeutics presumption by 143,304 shares during the 4th quarter. The estimated transaction worth is $5.43 million, calculated utilizing the mean unadjusted closing terms for the quarter. The quarter-end presumption worth accrued by $37.56 million, reflecting some trading enactment and terms appreciation.

OrbiMed Advisors’ Sionna Therapeutics holding present constitutes 2.99% of its 13F reportable AUM pursuing the sale.
Top holdings aft the filing:
- NASDAQ: EWTX: $385,091,379 (7.9% of AUM)
- NYSE: LLY: $323,693,616 (6.7% of AUM)
- NYSE: BSX: $230,680,255 (4.7% of AUM)
- NASDAQ: SVA: $184,466,170 (3.8% of AUM)
- NYSE: EW: $157,107,225 (3.2% of AUM)
As of Friday, SION shares were priced astatine $37.32, up 118% implicit the past twelvemonth and vastly outperforming the S&P 500’s astir 20% summation successful the aforesaid period.

Metric

Value

Price (as of Friday)	$37.32
Market Capitalization	$1.68 billion
Net Income (TTM)	($75.27 million)

Sionna Therapeutics develops biopharmaceutical products focused connected treatments for cystic fibrosis, targeting normalization of cystic fibrosis transmembrane conductance regulator (CFTR) function.
The steadfast operates a research-driven concern model, generating worth done the find and objective improvement of caller therapies, with gross imaginable chiefly from aboriginal merchandise approvals and licensing.
It serves healthcare providers, specialty clinics, and patients affected by cystic fibrosis, with a superior absorption connected the uncommon illness and biotechnology markets.

Sionna Therapeutics, Inc. is simply a biotechnology institution specializing successful the improvement of innovative therapies for cystic fibrosis. The company's strategy centers connected advancing medicines that code the underlying origin of the illness by targeting CFTR macromolecule dysfunction.

When a clinical-stage biotech banal much than doubles successful a year, trimming a presumption tin simply bespeak hazard absorption alternatively than fading conviction. That dynamic often appears successful healthcare-focused portfolios, wherever investors equilibrium high-upside cause improvement bets with much unchangeable holdings crossed the broader healthcare ecosystem.

Sionna Therapeutics seems to acceptable squarely successful that high-risk, high-reward category. The institution is processing therapies designed to reconstruct relation of the CFTR protein, the underlying origin of cystic fibrosis. Unlike galore biotech firms inactive searching for capital, Sionna is entering its adjacent signifier of objective improvement with fiscal flexibility. The institution ended 2025 with astir $310 cardinal successful cash, currency equivalents, and marketable securities, which absorption expects volition money operations into 2028.

The pipeline is besides progressing. A Phase 2a proof-of-concept proceedings evaluating its NBD1 stabilizer SION-719 is underway, portion different early-stage proceedings studying operation therapies is expected to nutrient topline information successful mid-2026. With the steadfast inactive commanding a astir $150 cardinal presumption wrong this portfolio, it truly seems similar this wasn’t a condemnation telephone astatine all.

Read Entire Article